Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control studyResearch in context
Summary: Background: After primary vaccination schemes with rAd26-rAd5 (Sputnik V), ChAdOx1 nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or heterologous boosters (Sputnik V, ChAdOx, Pfizer-BioNTech, Moderna) against SARS-CoV-2 infections, hospitalisations and de...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | The Lancet Regional Health. Americas |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667193X23001813 |
| _version_ | 1797670212197154816 |
|---|---|
| author | Soledad González Santiago Olszevicki Alejandra Gaiano Martín Salazar Lorena Regairaz Ana Nina Varela Baino Erika Bartel Teresa Varela Veronica V. González Martínez Santiago Pesci Lupe Marín Juan Ignacio Irassar Leticia Ceriani Enio Garcia Nicolás Kreplak Elisa Estenssoro Franco Marsico |
| author_facet | Soledad González Santiago Olszevicki Alejandra Gaiano Martín Salazar Lorena Regairaz Ana Nina Varela Baino Erika Bartel Teresa Varela Veronica V. González Martínez Santiago Pesci Lupe Marín Juan Ignacio Irassar Leticia Ceriani Enio Garcia Nicolás Kreplak Elisa Estenssoro Franco Marsico |
| author_sort | Soledad González |
| collection | DOAJ |
| description | Summary: Background: After primary vaccination schemes with rAd26-rAd5 (Sputnik V), ChAdOx1 nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or heterologous boosters (Sputnik V, ChAdOx, Pfizer-BioNTech, Moderna) against SARS-CoV-2 infections, hospitalisations and deaths has been scarcely studied. Methods: Test-negative, case–control study, conducted in Argentina during omicron BA.1 predominance, in adults ≥50 years old tested for SARS-CoV-2 who had received two or three doses of COVID-19 vaccines. Outcomes were COVID-associated infections, hospitalisations and deaths after administering mRNA and vectored boosters, < or ≥60 days from the last dose. Findings: Of 422,124 individuals tested for SARS-CoV-2, 221,993 (52.5%) tested positive; 190,884 (45.2%) and 231,260 (54.8%) had received 2-dose and 3-dose vaccination schemes, respectively. The 3-dose scheme reduced infections, hospitalisations and death (OR 0.81 [0.80–0.83]; 0.28 [0.25–0.32] and 0.25 [0.22–0.28] respectively), but protection dropped after 60 days to 1.04 [1.01–1.06]; 0.52 [0.44–0.61] and 0.38 [0.33–0.45]). Compared with 2-dose-schemes, homologous boosters after primary schemes with vectored-vaccines provided lower protection against infections < and ≥60 days (0.94 [0.92–0.97] and 1.05 [1.01–1.09], respectively) but protected against hospitalisations (0.30 [0.26–0.35]) and deaths (0.29 [0.25–0.33]), decreasing after 60 days (0.59 [0.47–0.74] and 0.51 [0.41–0.64], respectively). Heterologous boosters protected against infections (0.70 [0.68–0.71]) but decreased after 60 days (1.01 [0.98–1.04]) and against hospitalisations and deaths (0.26 [0.22–0.31] and 0.22 [0.18–0.25], respectively), which also decreased after 60 days (0.43 [0.35–0.53] and 0.33 [0.26–0.41], respectively). Heterologous boosters protected against infections when applied <60 days (0.70 [0.68–0.71], p < 0.001), against hospitalisations when applied ≥60 days (0.43 [0.35–0.53], p < 0.01), and against deaths < and ≥60 days (0.22 [0.18–0.25], p < 0.01 and 0.33 [0.26–0.41], p < 0.001). Interpretation: During omicron predominance, heterologous boosters such as viral vectored and mRNA vaccines, following Sputnik V, ChAdOx1, Sinopharm or heterologous primary schemes might provide better protection against death; this effect might last longer in individuals aged ≥50 than homologous boosters. Funding: None. |
| first_indexed | 2024-03-11T20:56:28Z |
| format | Article |
| id | doaj.art-1cfbeea635bb4a40955a58d0e0fd372c |
| institution | Directory Open Access Journal |
| issn | 2667-193X |
| language | English |
| last_indexed | 2024-03-11T20:56:28Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Americas |
| spelling | doaj.art-1cfbeea635bb4a40955a58d0e0fd372c2023-09-30T04:55:44ZengElsevierThe Lancet Regional Health. Americas2667-193X2023-11-0127100607Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control studyResearch in contextSoledad González0Santiago Olszevicki1Alejandra Gaiano2Martín Salazar3Lorena Regairaz4Ana Nina Varela Baino5Erika Bartel6Teresa Varela7Veronica V. González Martínez8Santiago Pesci9Lupe Marín10Juan Ignacio Irassar11Leticia Ceriani12Enio Garcia13Nicolás Kreplak14Elisa Estenssoro15Franco Marsico16Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaFaculty of Medical Sciences, National University of La Plata, ArgentinaImmunology Unit, Children's Hospital Sor Maria Ludovica, La Plata, Buenos AiresMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, ArgentinaMinistry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina; Faculty of Medical Sciences, National University of La Plata, ArgentinaFaculty of Exacts and Natural Sciences, University of Buenos Aires, Argentina; Corresponding author. Intendente Güiraldes, 2160, Buenos Aires, Argentina.Summary: Background: After primary vaccination schemes with rAd26-rAd5 (Sputnik V), ChAdOx1 nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or heterologous boosters (Sputnik V, ChAdOx, Pfizer-BioNTech, Moderna) against SARS-CoV-2 infections, hospitalisations and deaths has been scarcely studied. Methods: Test-negative, case–control study, conducted in Argentina during omicron BA.1 predominance, in adults ≥50 years old tested for SARS-CoV-2 who had received two or three doses of COVID-19 vaccines. Outcomes were COVID-associated infections, hospitalisations and deaths after administering mRNA and vectored boosters, < or ≥60 days from the last dose. Findings: Of 422,124 individuals tested for SARS-CoV-2, 221,993 (52.5%) tested positive; 190,884 (45.2%) and 231,260 (54.8%) had received 2-dose and 3-dose vaccination schemes, respectively. The 3-dose scheme reduced infections, hospitalisations and death (OR 0.81 [0.80–0.83]; 0.28 [0.25–0.32] and 0.25 [0.22–0.28] respectively), but protection dropped after 60 days to 1.04 [1.01–1.06]; 0.52 [0.44–0.61] and 0.38 [0.33–0.45]). Compared with 2-dose-schemes, homologous boosters after primary schemes with vectored-vaccines provided lower protection against infections < and ≥60 days (0.94 [0.92–0.97] and 1.05 [1.01–1.09], respectively) but protected against hospitalisations (0.30 [0.26–0.35]) and deaths (0.29 [0.25–0.33]), decreasing after 60 days (0.59 [0.47–0.74] and 0.51 [0.41–0.64], respectively). Heterologous boosters protected against infections (0.70 [0.68–0.71]) but decreased after 60 days (1.01 [0.98–1.04]) and against hospitalisations and deaths (0.26 [0.22–0.31] and 0.22 [0.18–0.25], respectively), which also decreased after 60 days (0.43 [0.35–0.53] and 0.33 [0.26–0.41], respectively). Heterologous boosters protected against infections when applied <60 days (0.70 [0.68–0.71], p < 0.001), against hospitalisations when applied ≥60 days (0.43 [0.35–0.53], p < 0.01), and against deaths < and ≥60 days (0.22 [0.18–0.25], p < 0.01 and 0.33 [0.26–0.41], p < 0.001). Interpretation: During omicron predominance, heterologous boosters such as viral vectored and mRNA vaccines, following Sputnik V, ChAdOx1, Sinopharm or heterologous primary schemes might provide better protection against death; this effect might last longer in individuals aged ≥50 than homologous boosters. Funding: None.http://www.sciencedirect.com/science/article/pii/S2667193X23001813Vaccination |
| spellingShingle | Soledad González Santiago Olszevicki Alejandra Gaiano Martín Salazar Lorena Regairaz Ana Nina Varela Baino Erika Bartel Teresa Varela Veronica V. González Martínez Santiago Pesci Lupe Marín Juan Ignacio Irassar Leticia Ceriani Enio Garcia Nicolás Kreplak Elisa Estenssoro Franco Marsico Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control studyResearch in context The Lancet Regional Health. Americas Vaccination |
| title | Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control studyResearch in context |
| title_full | Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control studyResearch in context |
| title_fullStr | Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control studyResearch in context |
| title_full_unstemmed | Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control studyResearch in context |
| title_short | Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control studyResearch in context |
| title_sort | protection of homologous and heterologous boosters after primary schemes of rad26 rad5 chadox1 ncov 19 and bbibp corv during the omicron outbreak in adults of 50 years and older in argentina a test negative case control studyresearch in context |
| topic | Vaccination |
| url | http://www.sciencedirect.com/science/article/pii/S2667193X23001813 |
| work_keys_str_mv | AT soledadgonzalez protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT santiagoolszevicki protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT alejandragaiano protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT martinsalazar protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT lorenaregairaz protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT ananinavarelabaino protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT erikabartel protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT teresavarela protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT veronicavgonzalezmartinez protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT santiagopesci protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT lupemarin protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT juanignacioirassar protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT leticiaceriani protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT eniogarcia protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT nicolaskreplak protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT elisaestenssoro protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext AT francomarsico protectionofhomologousandheterologousboostersafterprimaryschemesofrad26rad5chadox1ncov19andbbibpcorvduringtheomicronoutbreakinadultsof50yearsandolderinargentinaatestnegativecasecontrolstudyresearchincontext |